Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of PF-06939926 gene therapy in ambulant boys with Duchenne muscular dystrophy
jRCT2051210011Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- May 2021
- Modality
- Gene Therapies
01
Overview
Phase 3, randomised, double-blind trial of fordadistrogene movaparvovec in Duchenne muscular dystrophy (DMD) (2 cohorts), sponsored by Pfizer. Primary endpoint: Change from Baseline in North Star Ambulatory Assessment (NSAA). Started May 2021; status: active, not recruiting.
02
Drugs
fordadistrogene movaparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2051210011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210011.